Colorectal CancerNCT05754229
Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy
A study testing AI-assisted colonoscopy in people with Colorectal Cancer and Colorectal Adenoma, run by Ismail Gögenur at 4 sites in Denmark.
Trial summary
The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are: How high is the specificity of the AI system when characterizing colorectal polyps Participants will receive a standard colonoscopy, assisted by the artificial… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
- What is being tested?
- AI-assisted colonoscopy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 395 participants
- Where
- 4 sitesDenmark
- Study dates
- 1 Oct 2022to 21 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for
- Diagnostic colonoscopy due to symptoms/signs or
- Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy)
Who cannot join
- Referral for removal of previous detected polyps
- Emergency colonoscopy
- Control colonoscopy due to inflammatory bowel disease (IBD)
Trial locations and contacts
4 sites in 1 country.
Denmark4 sites
Holbæk Hospital
Holbæk, 4300
Zealand University Hospital
Køge, 4600
Næstved Hospital
Næstved, 4700
Nykøbing Falster County Hospital
Nykøbing Falster, 4800
About this study
Official title: Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy - A Prospective Quality Assurance Study
The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are:
- How high is the specificity of the AI system when characterizing colorectal polyps
Participants will receive a standard colonoscopy, assisted by the artificial intelligence (AI) assisted system GI Genius.
Researchers will compare the AI system´s characterization with the histopathology to see how accurate the system is.
Read the detailed description
Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard.
Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy.
Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Studies have shown that AI contributes to a significantly higher adenoma detection rate (ADR), compared colonoscopies without assistance of an AI system.There have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI-system, since the increased detection of small polyps may lead to unnecessary polypectomy.
With the development of computer-aided polyp characterization (CADx) systems, it is possible to use AI for decision support and not only for detection. There is no evidence yet that the CADx system increases the sensitivity for small neoplastic polyps when used by non-expert endoscopists (accredited for standard colonoscopy), but it may improve the clinicians confidence, and increase the specificity for optical diagnosis (Barua et al).
Diminutive polyps (1-5 mm) in the rectosigmoid colon can be left in situ when diagnosed with high confidence with a sensitivity of at least 90% and a specificity of at least 80%. To implement the resect-and-discard strategy, a sensitivity of at least 80% is acceptable. This is recommended by the European Society of Gastrointestinal Endoscopy (ESGE) as a strategy to decrease the unnecessary removal of small polyps with a negligible risk of harbouring cancer. Although the resect-and-discard strategy is assessed to be a safe and cost-effective method, it is important to be cautious with lesions in the right colon due to their malignant potential.
Reliable CADx systems could enable a more targeted removal of neoplastic polyps, while diminutive non-neoplastic polyps could be left behind. The potential excessive workload due to the CADe system could therefore theoretically be avoided by adding the CADx system.
The results so far are promising, suggesting that AI-assisted colonoscopy is superior to conventional colonoscopy when it comes to polyp and adenoma detection. Continued improvement of CADx systems in differentiating the pathology of colorectal lesions is needed, as well as additional clinical studies to assess the potential value of the CADx system.
The overall aim of this research is to investigate the quality, and the possible benefits of AI-assistance in colonoscopy. Hopefully this can contribute to a more accurate, safe, and targeted diagnosis and treatment of patients in the future.
The investigators have designed a quality assurance study to investigate the effect of real time AI-assisted colonoscopy with the CADx system (GI Genius, Medtronic). This study "REG-093-2022" is a substudy to the RCT "REG-092-2022". The investigators wish to evaluate the diagnostic accuracy of the CADx system.
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
- Being tested
- AI-assisted colonoscopy
- Keywords
- Artificial intelligence-assisted colonoscopy, Computer-aided polyp characterization, Colorectal adenoma
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-assisted colonoscopyDevice
The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
| Study group | Role | What they receive |
|---|---|---|
| AI-assisted colonoscopy | Other | The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic). Receives: Device: AI-assisted colonoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
Measured: 5 Months
True negative findings: Non-adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
Measured: 5 Months
False positive findings: Non-adenomas (histopathologically verified) characterized as adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
Measured: 5 Months
False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
Measured: 5 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2023
- Study start1 Oct 2022
- Primary completion3 Mar 2023
- Study completion21 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 395 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ismail Gögenur
- Sponsor type
- University, hospital or other
- Collaborators
- Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital
- Responsible party
- Sponsor-investigator, Ismail Gögenur, Zealand University Hospital
- Investigators
- Ronja Lagström, MD, Principal investigator, Zealand University Hospital, Køge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05754229
- Sponsor's protocol ID
- REG-093-2022
- Status last verified
- Aug 2025
- First submitted
- 3 Feb 2023
- Last updated
- 27 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy - A Prospective Quality Assurance Study
- ClinicalTrials.gov ID
- NCT05754229
- Acronym / sponsor ID
- REG-093-2022
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
- Keywords
- Artificial intelligence-assisted colonoscopy, Computer-aided polyp characterization, Colorectal adenoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 395 participants (actual)
- Lead sponsor
- Ismail GögenurUniversity, hospital or other
- Collaborators
- Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital
- Study start
- 1 Oct 2022 (actual)
- Primary completion
- 3 Mar 2023 (actual)
- Study completion
- 21 Apr 2026 (actual)
- First posted
- 3 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are:
- How high is the specificity of the AI system when characterizing colorectal polyps
Participants will receive a standard colonoscopy, assisted by the artificial intelligence (AI) assisted system GI Genius.
Researchers will compare the AI system´s characterization with the histopathology to see how accurate the system is.
Detailed description
Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard.
Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy.
Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Studies have shown that AI contributes to a significantly higher adenoma detection rate (ADR), compared colonoscopies without assistance of an AI system.There have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI-system, since the increased detection of small polyps may lead to unnecessary polypectomy.
With the development of computer-aided polyp characterization (CADx) systems, it is possible to use AI for decision support and not only for detection. There is no evidence yet that the CADx system increases the sensitivity for small neoplastic polyps when used by non-expert endoscopists (accredited for standard colonoscopy), but it may improve the clinicians confidence, and increase the specificity for optical diagnosis (Barua et al).
Diminutive polyps (1-5 mm) in the rectosigmoid colon can be left in situ when diagnosed with high confidence with a sensitivity of at least 90% and a specificity of at least 80%. To implement the resect-and-discard strategy, a sensitivity of at least 80% is acceptable. This is recommended by the European Society of Gastrointestinal Endoscopy (ESGE) as a strategy to decrease the unnecessary removal of small polyps with a negligible risk of harbouring cancer. Although the resect-and-discard strategy is assessed to be a safe and cost-effective method, it is important to be cautious with lesions in the right colon due to their malignant potential.
Reliable CADx systems could enable a more targeted removal of neoplastic polyps, while diminutive non-neoplastic polyps could be left behind. The potential excessive workload due to the CADe system could therefore theoretically be avoided by adding the CADx system.
The results so far are promising, suggesting that AI-assisted colonoscopy is superior to conventional colonoscopy when it comes to polyp and adenoma detection. Continued improvement of CADx systems in differentiating the pathology of colorectal lesions is needed, as well as additional clinical studies to assess the potential value of the CADx system.
The overall aim of this research is to investigate the quality, and the possible benefits of AI-assistance in colonoscopy. Hopefully this can contribute to a more accurate, safe, and targeted diagnosis and treatment of patients in the future.
The investigators have designed a quality assurance study to investigate the effect of real time AI-assisted colonoscopy with the CADx system (GI Genius, Medtronic). This study "REG-093-2022" is a substudy to the RCT "REG-092-2022". The investigators wish to evaluate the diagnostic accuracy of the CADx system.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AI-assisted colonoscopy | Other | Device: AI-assisted colonoscopyThe patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for
- Diagnostic colonoscopy due to symptoms/signs or
- Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy)
Key exclusion criteria (3 listed)
- Referral for removal of previous detected polyps
- Emergency colonoscopy
- Control colonoscopy due to inflammatory bowel disease (IBD)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-assisted colonoscopyThe patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic). | Device | AI-assisted colonoscopy |
Primary outcome
True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system
Time frame: 5 Months
Data from the AI system will be compared with the histopathological data for each removed polyp
True negative findings: Non-adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Time frame: 5 Months
Data from the AI system will be compared with the histopathological data for each removed polyp
False positive findings: Non-adenomas (histopathologically verified) characterized as adenomas by the AI system
Time frame: 5 Months
Data from the AI system will be compared with the histopathological data for each removed polyp
False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Time frame: 5 Months
Data from the AI system will be compared with the histopathological data for each removed polyp
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
Related trials for Colorectal Cancer
RecruitingPhase 1/2
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
Recruiting
Family Communications After Genetic Testing
Colon Adenocarcinoma, Colorectal Adenocarcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 3
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Left-sided Colorectal Cancer
RecruitingPhase 1/2
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ronja Lagström, MD principal investigator
Zealand University Hospital, Køge
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-assisted colonoscopy in people with Colorectal Cancer and Colorectal Adenoma, run by Ismail Gögenur at 4 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system (time frame: 5 Months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.